AlphaLiquid HRR
Blood-based targeted NGS assay for homologous-recombination-repair genomic profiling in solid tumors.
- Developer
- IMBdx
- Intended use
- Other
- Cancer scope
- Solid tumors
- Specimen
- Plasma
- Molecular modality
- DNA mutation
- Current version
- Current AlphaLiquid HRR blood-based NGS configuration; official 2026 IMBdx announcement expands HRR panel from 15 to 19 genes
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.